"Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis"
Wilson R et al. "Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis" J Antimicrob Chemother 1999; 44: 501-513.
"The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis"
De Abate CA et al. "The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis" Respir Med 2000; 94: 1029-1037.
"Medical officer's review of NDA 21-085. Indication: Acute bacterial exacerbation of chronic bronchitis"
Food and Drug Administration. 12 November
Food and Drug Administration "Medical officer's review of NDA 21-085. Indication: acute bacterial exacerbation of chronic bronchitis" 12 November 1999: 34-53.
(1999), pp. 34-53
6
0034811145
"A multinational, multicentre, non blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis"
Schaberg T et al. "A multinational, multicentre, non blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis" J Int Med Res 2001; 29: 314-328.
"Oral moxifloxacin vs highdosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults"
Petitpretz P et al. "Oral moxifloxacin vs highdosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults" Chest 2001; 119 (1): 185-195.
"Medical Officer's review of NDA 21-085. Indication: Community-acquired pneumonia"
Food and drug Administration. 15 November
Food and drug Administration "Medical Officer's review of NDA 21-085. Indication: community-acquired pneumonia" 15 November 1999: 5-20.
(1999), pp. 5-20
9
0034933394
"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia"
Hoeffken G et al. "The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia" Respir Med 2001; 95: 553-564.
"A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults"
Siegert R et al. "A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults" Respir Med 2000; 94: 337-344.
Food and Drug Administration - Center for drug evaluation and research. 12 September
Food and Drug Administration - Center for drug evaluation and research "Application number 21-085-Statistical reviews" 12 September 1999: 3-11.
(1999), pp. 3-11
13
0034743452
"Moxifloxacin versus amoxycillin clavulanate in the treatment of acute maxillary sinusitis: A primary care experience"
Rakkar S et al. "Moxifloxacin versus amoxycillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience" Int J Clin Pract 2001; 55 (5): 309-315.
